Hansa Biopharma: Increase of the number of votes
Lund, Sweden, July 31, 2023. Hansa Biopharma AB “Hansa” or the “Company”, (Nasdaq Stockholm: HNSA), the pioneer enzyme technology for rare immunological conditions, today announces that the number of outstanding votes in Hansa have increased during the month of July 2023 as a result of the conversion of a total of 227,834 class C shares to a total of 227,834 ordinary shares. The conversion was carried out by Hansa in order to deliver ordinary shares to participants in Hansa’s incentive program adopted at the annual general meeting in 2020 and to secure social contributions arising as a